

Grifols expands U.S. diagnostic manufacturing with a new facility in San Diego

- *Grifols Diagnostic has begun producing its DG Gel card technology and reagent red blood cells, vital to pretransfusion patient and donor testing, at its new manufacturing facility at the company's campus in San Diego, California, following FDA approvals*
- *New product lines further strengthen production portfolio at the campus, which already includes reagents for the Procleix Panther System to screen blood, plasma and tissues for infectious diseases*
- *Over the last decade and across its businesses, Grifols has been strategically broadening its manufacturing footprint in the U.S. to be closer to patients and donors in this important growth market*

Barcelona, Spain, October 16, 2025 - Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines and innovative diagnostic solutions, today announced it has started manufacturing Grifols DG Gel cards and reagent red blood cell (RRBCs) at the company's new plant in San Diego, California, following approvals from the Food and Drug Administration (FDA).

Production of this key technology, used in blood type testing to ensure transfusion compatibility between donors and patients, will serve the growing demand for blood typing solutions in the U.S. Each year nearly 16 million blood components¹ are transfused in this highly specialized market, which is expected to grow 6.9% by 2030, to USD 1.2 billion.²

The facility has also started production of Grifols reagent red blood cells (RRBCs) after receiving FDA licensing approval. These RRBCs are specially formulated at a concentration of 0.8% and used in Grifols' DG Gel cards as part of blood type identification and to antibody detection, helping ensure transfusion safety in compatibility testing.

"The U.S. continues to be the primary market for our diagnostic business and therefore it is crucial that we expand and diversify our operations in this country," said Antonio Martinez, president Grifols Diagnostic. "Adding U.S. manufacturing of the DG Gel card system product line as well as the red blood cell reagents in our new facility are important steps in being closer to our U.S. patients and donors to meet their growing transfusion medicine needs. Our San Diego campus is today one of the most important hubs for transfusion medicine in the world and one of the few dedicated exclusively to this field."

Grifols has been expanding its manufacturing operations in the U.S. over the last decade. The company owns and operates one of the largest plasma fractionation facilities in the world in Clayton,

¹ American Red Cross. (n.d.). Blood needs & blood supply. <https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html>

² Grand View Research. (n.d.). The United States blood typing market size & outlook, 2030. Horizon by Grand View Research. <https://www.grandviewresearch.com/horizon/outlook/blood-typing-market/united-states>

North Carolina, where it continues to invest and increase capacity. Grifols' U.S. manufacturing footprint also includes four California locations, including Los Angeles, Vista, Emeryville and San Diego, the last two dedicated to the company's Diagnostic business.

High-tech plant expands Grifols' global diagnostic capacity

The 73,541-square-foot facility, designed by Grifols Engineering, features highly automated production technologies, including a state-of-the-art quality-control laboratory, a warehouse and office space. The new facility nearly doubles the size of the campus.

With production of both DG Gel cards and RRBCs ramping up at Grifols San Diego, the campus expands its output beyond the reagents it already manufactures for the Procleix Panther System, the company's leading blood and plasma screening platform. As a key Diagnostic hub, the site spans more than 196,000 square feet and employs over 230 professionals covering a wide range of areas that also include R&D, quality, finance, facilities and human resources.

The company's production of DG Gel cards and RRBCs in the U.S. adds to that of its two plants in Europe (Spain and Switzerland) and Australia, that were already producing these products. This diversification can quickly address evolving customer needs wherever they may be as well as cover any necessary supply-chain contingencies.

DG Gel cards, a success story from Grifols Diagnostic

Grifols Diagnostic, a renowned global transfusion medicine leader, owns the high-quality DG Gel card technology critical in determining blood groups to ensure transfusion compatibility. It also identifies other clinical complications, such as the fetal risk in cases of Rh incompatibility in pregnant women.

Grifols DG Gel system platforms, based on column agglutination technology, is processed on the Erytra and Erytra Eflexis instrumentation, also manufactured by Grifols, to quickly and precisely generate results for blood and plasma donation centers and immunohematology laboratories.

Since launching its DG Gel cards in the U.S. more than 10 years ago, Grifols' market share has steadily increased while also contributing to the current double-digit growth of the company's Diagnostic business in North America.

Grifols Diagnostic Business Unit revenue grew 2.8% at constant currency in the first half of 2025, compared to the same period in 2024. The Blood Typing business is growing at a double-digit rate. Grifols Diagnostic achieved 15% growth in North America in 2024.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

INVESTORS:

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval

in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.